The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis

Background Markers of kidney dysfunction such as proteinuria or albuminuria have been reported to be associated with coronary heart disease, but the consistency and strength of any such relationship has not been clearly defined. This lack of clarity has led to great uncertainty as to how proteinuria should be treated in the assessment and management of cardiovascular risk. We therefore undertook a systematic review of published cohort studies aiming to provide a reliable estimate of the strength of association between proteinuria and coronary heart disease. Methods and Findings A meta-analysis of cohort studies was conducted to obtain a summary estimate of the association between measures of proteinuria and coronary risk. MEDLINE and EMBASE were searched for studies reporting an age- or multivariate-adjusted estimate and standard error of the association between proteinuria and coronary heart disease. Studies were excluded if the majority of the study population had known glomerular disease or were the recipients of renal transplants. Two independent researchers extracted the estimates of association between proteinuria (total urinary protein >300 mg/d), microalbuminuria (urinary albumin 30–300 mg/d), macroalbuminuria (urinary albumin >300 mg/d), and risk of coronary disease from individual studies. These estimates were combined using a random-effects model. Sensitivity analyses were conducted to examine possible sources of heterogeneity in effect size. A total of 26 cohort studies were identified involving 169,949 individuals and 7,117 coronary events (27% fatal). The presence of proteinuria was associated with an approximate 50% increase in coronary risk (risk ratio 1.47, 95% confidence interval [CI] 1.23–1.74) after adjustment for known risk factors. For albuminuria, there was evidence of a dose–response relationship: individuals with microalbuminuria were at 50% greater risk of coronary heart disease (risk ratio 1.47, 95% CI 1.30–1.66) than those without; in those with macroalbuminuria the risk was more than doubled (risk ratio 2.17, 1.87–2.52). Sensitivity analysis indicated no important differences in prespecified subgroups. Conclusion These data confirm a strong and continuous association between proteinuria and subsequent risk of coronary heart disease, and suggest that proteinuria should be incorporated into the assessment of an individual's cardiovascular risk.

[1]  B. Astor,et al.  Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. , 2007, Archives of internal medicine.

[2]  M. Woodward,et al.  Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia–Pacific region , 2007, Journal of hypertension.

[3]  Rowena J Dolor,et al.  Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. , 2007, Journal of the American College of Cardiology.

[4]  K. Shimamoto,et al.  Other health matters to be considered for the Asian population: hypertensive patients at high risk , 2006 .

[5]  D. de Zeeuw,et al.  Evaluation of measures of urinary albumin excretion. , 2006, American journal of epidemiology.

[6]  H. Parving,et al.  Microalbuminuria as an early marker for cardiovascular disease. , 2006, Journal of the American Society of Nephrology : JASN.

[7]  James R. Madison,et al.  Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program. , 2006, Archives of internal medicine.

[8]  F. Irie,et al.  The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. , 2006, Kidney international.

[9]  P. McKeigue,et al.  Microalbuminuria and coronary heart disease risk in an ethnically diverse UK population: a prospective cohort study. , 2005, Journal of the American Society of Nephrology : JASN.

[10]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[11]  W. Hoy,et al.  Albuminuria and incident coronary heart disease in Australian Aboriginal people. , 2005, Kidney international.

[12]  S. Haffner,et al.  Microalbuminuria as a predictor of myocardial infarction in a Mexican population: the Mexico City Diabetes Study. , 2005, Kidney international. Supplement.

[13]  E. Agardh,et al.  Nephropathy, but not retinopathy, is associated with the development of heart disease in Type 1 diabetes: a 12‐year observation study of 462 patients , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[14]  M. Nieminen,et al.  Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[15]  R. Atkins,et al.  Chronic kidney disease in the general population. , 2005, Advances in chronic kidney disease.

[16]  M. Woodward,et al.  Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. , 2005, International journal of epidemiology.

[17]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[18]  M. Woodward,et al.  Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 000 participants. , 2004, International journal of epidemiology.

[19]  K. Borch-Johnsen,et al.  Preventive cardiology: abstractVery low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes☆ , 2004 .

[20]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[21]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[22]  Constance K Haan,et al.  Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[23]  N. Day,et al.  A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. , 2004, American journal of epidemiology.

[24]  N. Chaturvedi,et al.  Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. , 2004, Diabetes care.

[25]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[26]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[27]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[28]  Mark Woodward,et al.  Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. , 2003, International journal of epidemiology.

[29]  David W Dunstan,et al.  Prevalence of kidney damage in Australian adults: The AusDiab kidney study. , 2003, Journal of the American Society of Nephrology : JASN.

[30]  R. Leelawattana,et al.  Causes of death, incidence and risk factors of cardiovascular diseases in Thai type 2 diabetic patients: a 5 year follow-up study. , 2003, Diabetes research and clinical practice.

[31]  M. Woodward,et al.  The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. , 2003, Diabetes care.

[32]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[34]  Jiang He,et al.  Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. , 2002, Journal of the American Society of Nephrology : JASN.

[35]  K. Jablonski,et al.  Accuracy of lipoprotein lipids and apoproteins in predicting coronary heart disease in diabetic American Indians. The Strong Heart Study. , 2002, Annals of epidemiology.

[36]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[37]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[38]  A. T. N. Group,et al.  Risk factors for cardiovascular mortality and morbidity: The WHO multinational study of vascular disease in diabetes. , 2001, Diabetologia.

[39]  C. Florkowski,et al.  Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study. , 2001, Diabetes research and clinical practice.

[40]  J. Danesh,et al.  Fibrin D-Dimer and Coronary Heart Disease: Prospective Study and Meta-Analysis , 2001, Circulation.

[41]  D. Levy,et al.  Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. , 2000, The American journal of medicine.

[42]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[43]  R. Klein,et al.  The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. , 2000, Archives of internal medicine.

[44]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[45]  M. Schroll,et al.  Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. , 2000, Hypertension.

[46]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[47]  M. Schroll,et al.  Urinary albumin excretion. An independent predictor of ischemic heart disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[48]  M. Laakso,et al.  Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. , 1999, Circulation.

[49]  A. Fitzgerald,et al.  Microalbuminuria and coronary heart disease in NIDDM: an incidence study. , 1998, Diabetes.

[50]  M. Laakso,et al.  Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. , 1996, Stroke.

[51]  M. Knuiman,et al.  Microalbuminuria in type 2 diabetes: an independent predictor of cardiovascular mortality. , 1996, Australian and New Zealand journal of medicine.

[52]  T. Nakayama,et al.  A 15.5-year cohort study on risk factors for possible myocardial infarction and sudden death within 24 hours in a rural Japanese community. , 1996, Journal of epidemiology.

[53]  A. Sasaki,et al.  Mortality from coronary heart disease and cerebrovascular disease and associated risk factors in diabetic patients in Osaka District, Japan. , 1995, Diabetes research and clinical practice.

[54]  J. Madans,et al.  Proteinuria as a biomarker: risk of subsequent morbidity and mortality. , 1994, Environmental research.

[55]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[56]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[57]  B. Scribner,et al.  Accelerated atherosclerosis in prolonged maintenance hemodialysis. , 1974, The New England journal of medicine.